Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study
ResTORbio, a new company developing tech spun out of Novartis, has raised $40 million in a Series B round to speed its anti-aging program through the clinic.
The startup, which was set up earlier this year as a subsidiary of Boston-based PureTech Health, has brought in $65 million since its inception. The money will be used to advance the company’s lead immunotherapy program meant to reduce respiratory tract infections in elderly subjects, which is already in Phase IIb. Results are expected next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.